BUZZ-Ovid <a href="https://laohu8.com/S/LENZ">Therapeutics</a> jumps after seizure treatment shows promise in trial** Shares of drug developer Ovid Therapeutics OVID.O rise 20% to $1.97 premarket
** Co says its experimental epilepsy drug, OV329, showed strong signs of effectiveness in early-stage trial
** The drug is being developed to treat drug-resistant forms of epilepsy, a type of seizure that affects only one side of the brain and body
** The study showed OV329 helped raise levels of a calming chemical in the brain by blocking an enzyme that breaks it down, which may help reduce seizures, co says
** Ovid said OV329 worked as well as or better than vigabatrin, an older medicine used to treat seizures
** As of last close, stock was up 75% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.